Harm reduction in the time of COVID-19: Case study of homelessness and drug use in Dublin, Ireland.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
01 2021
Historique:
received: 29 07 2020
revised: 15 09 2020
accepted: 18 09 2020
pubmed: 10 11 2020
medline: 16 3 2021
entrez: 9 11 2020
Statut: ppublish

Résumé

Dublin appears to have performed very well as compared to various scenarios for COVID-19 mortality amongst homeless and drug using populations. The experience, if borne out by further research, provides important lessons for policy discussions on the pandemic, as well as broader lessons about pragmatic responses to these key client groups irrespective of COVID-19. The overarching lesson seems that when government policy is well coordinated and underpinned by a science-driven and fundamentally pragmatic approach, morbidity and mortality can be reduced. Within this, the importance of strategic clarity and delivery, housing, lowered thresholds to methadone provision, Benzodiazepine (BZD) provision and Naloxone availability were key determinants of policy success. Further, this paper argues that the rapid collapse in policy barriers to these interventions that COVID-19 produced should be secured and protected while further research is conducted.

Identifiants

pubmed: 33166825
pii: S0955-3959(20)30304-2
doi: 10.1016/j.drugpo.2020.102966
pmc: PMC7647898
pii:
doi:

Substances chimiques

Benzodiazepines 12794-10-4
Naloxone 36B82AMQ7N
Methadone UC6VBE7V1Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102966

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare that they have no conflict of interest.

Références

Ann Intern Med. 2020 Jul 7;173(1):59-60
pubmed: 32240291
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):817-823
pubmed: 32540735
J Addict Med. 2019 May/Jun;13(3):182-187
pubmed: 30543543
Addiction. 2020 Jun;115(6):1007-1010
pubmed: 32250482
BMC Med. 2020 Jul 31;18(1):241
pubmed: 32731868
MMWR Morb Mortal Wkly Rep. 2020 May 01;69(17):523-526
pubmed: 32352954
CMAJ. 2009 Dec 8;181(12):891-6
pubmed: 19969578
Psychol Trauma. 2020 Aug;12(S1):S108-S110
pubmed: 32496102
Psychiatry Res. 2020 Jul;289:113096
pubmed: 32405115
MMWR Morb Mortal Wkly Rep. 2020 May 01;69(17):521-522
pubmed: 32352957
Aust N Z J Psychiatry. 2003 Aug;37(4):458-63
pubmed: 12873331
J Psychopharmacol. 2017 Jan;31(1):62-66
pubmed: 28072037
Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481
pubmed: 29543325
J Psychopharmacol. 2004 Sep;18(3):293-335
pubmed: 15358975
Prim Care Respir J. 2012 Dec;21(4):377-83
pubmed: 22875144
Asian J Psychiatr. 2020 Jun;51:102064
pubmed: 32305033
Addiction. 2009 Jan;104(1):13-24
pubmed: 18983627
Basic Clin Neurosci. 2020 Mar-Apr;11(2):207-216
pubmed: 32855780
J Med Toxicol. 2019 Jan;15(1):4-11
pubmed: 30066312
Addiction. 2010 Nov;105(11):1875-6
pubmed: 21064246
Public Health Rep. 2020 Jul/Aug;135(4):435-441
pubmed: 32516035
J Infect. 2008 Jun;56(6):437-45
pubmed: 18440646
Chest. 2020 Aug;158(2):477-478
pubmed: 32389724
BMC Psychiatry. 2016 May 27;16:168
pubmed: 27234965
J Addict Med. 2020 Jul/Aug;14(4):e6-e7
pubmed: 32404651
Cochrane Database Syst Rev. 2015;(5):CD009652
pubmed: 26106751
Addiction. 2010 Nov;105(11):1870-4
pubmed: 20456294
Ann Intern Med. 2020 Jul 7;173(1):57-58
pubmed: 32240283
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
Br J Clin Pharmacol. 2014 Feb;77(2):272-84
pubmed: 23145768
Addiction. 2010 Nov;105(11):1876-7
pubmed: 21064247
CNS Drugs. 2009;23(1):19-34
pubmed: 19062773
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
J Urban Health. 2020 Aug;97(4):448-456
pubmed: 32720298
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
Drug Alcohol Rev. 2000 Dec;19(4):401-405
pubmed: 28474445
Psychiatr Danub. 2010 Mar;22(1):90-3
pubmed: 20305598
Addiction. 2007 Apr;102(4):616-22
pubmed: 17286641

Auteurs

Austin O'Carroll (A)

COVID-19 Clinical Lead for Homelessness in Dublin, Grangegorman Upper, Arran Quay, Dublin, Ireland.

Tony Duffin (T)

CEO of Ana Liffey Drug Project, 48 Middle Abbey St, North City, Dublin 1, D01 TY74, Ireland. Electronic address: tony.duffin@aldp.ie.

John Collins (J)

Director of Academic Engagement, the Global Initiative Against Transnational Organized Crime, Schwarzenbergplatz 1, 1010 Vienna, Austria. Electronic address: john.collins@globalinitiative.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH